Adagio shares soar on antibody potential against new COVID variant omicron

Stifel analyst Stephen Willey believes vaccines alone are unlikely to sufficiently address the COVID-19 pandemic.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.